Literature DB >> 19257811

Differentiation of Wharton's jelly primitive stromal cells into insulin-producing cells in comparison with bone marrow mesenchymal stem cells.

Li-Fang Wu1, Ni-Na Wang, Yuan-Sheng Liu, Xing Wei.   

Abstract

Primitive stromal cells can be isolated from umbilical cord Wharton's jelly (UC-PSCs). Umbilical cord can be easily obtained without causing pain to donors, and the procedure avoids ethical and technical issues. UC-PSCs are more primitive than mesenchymal stem cells (MSCs) isolated from some other tissue sources. In this study, UC-PSCs were induced to differentiate into insulin-producing cells, and compared with bone marrow-derived MSCs (BM-MSCs) for their pancreatic differentiation potential. UC-PSCs showed significantly higher proliferation than BM-MSCs. During pancreatic induction, UC-PSCs formed larger islet-like cell clusters than BM-MSCs. Immunocytochemical analysis showed that higher expression of the pancreatic-specific transcription factor PDX-1 was detected in differentiated UC-PSCs than in differentiated BM-MSCs. Flow cytometry analysis demonstrated that the percentage of differentiated UC-PSCs expressing pancreatic-specific marker C-peptide was 72% higher than differentiated BM-MSCs. Radioimmunoassay revealed that differentiated UC-PSCs secreted significantly more insulin than differentiated BM-MSCs. These results demonstrated that UC-PSCs had higher pancreatic differentiation potential than BM-MSCs. Therefore, UC-PSCs are more suitable for pancreatic tissue engineering in the treatment of type I diabetes than BM-MSCs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19257811     DOI: 10.1089/ten.TEA.2008.0579

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  39 in total

Review 1.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

2.  Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art.

Authors:  Arianna Malgieri; Eugenia Kantzari; Maria Patrizia Patrizi; Stefano Gambardella
Journal:  Int J Clin Exp Med       Date:  2010-09-07

3.  Protective effect of rat pancreatic progenitors cells expressing Pdx1 and nestin on islets survival and function in vitro and in vivo.

Authors:  Shu-Yan Zhou; Yu-Sen Zhang; Qing Li; Yi Zhang; Hui Qi; Han-Xin Zhou; Chun-Yan Deng; Fu-Rong Li
Journal:  J Physiol Biochem       Date:  2012-05-29       Impact factor: 4.158

4.  Quantitative Raman spectral changes of the differentiation of mesenchymal stem cells into islet-like cells by biochemical component analysis and multiple peak fitting.

Authors:  Xin Su; Shaoyin Fang; Daosen Zhang; Qinnan Zhang; Yingtian He; Xiaoxu Lu; Shengde Liu; Liyun Zhong
Journal:  J Biomed Opt       Date:  2015       Impact factor: 3.170

Review 5.  A review of clinical trials: mesenchymal stem cell transplant therapy in type 1 and type 2 diabetes mellitus.

Authors:  Jang Cho; Matthew D'Antuono; Michael Glicksman; Jing Wang; Jacqueline Jonklaas
Journal:  Am J Stem Cells       Date:  2018-10-01

6.  Improving the efficacy of type 1 diabetes therapy by transplantation of immunoisolated insulin-producing cells.

Authors:  Phan Kim Ngoc; Pham Van Phuc; Truong Hai Nhung; Duong Thanh Thuy; Nguyen Thi Minh Nguyet
Journal:  Hum Cell       Date:  2011-05-13       Impact factor: 4.174

7.  In vitro evaluation of different protocols for the induction of mesenchymal stem cells to insulin-producing cells.

Authors:  Fatemeh Seyedi; Alireza Farsinejad; Mojgan Moshrefi; Seyed Noureddin Nematollahi-Mahani
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-04-22       Impact factor: 2.416

8.  Promoting the recovery of injured liver with poly (3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) scaffolds loaded with umbilical cord-derived mesenchymal stem cells.

Authors:  Pengshan Li; Jin Zhang; Jing Liu; Huan Ma; Jie Liu; Puchang Lie; Yuechun Wang; Gexiu Liu; Huilan Zeng; Zhizhong Li; Xing Wei
Journal:  Tissue Eng Part A       Date:  2014-11-14       Impact factor: 3.845

9.  Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome.

Authors:  Junji Xu; Dandan Wang; Dayong Liu; Zhipeng Fan; Huayong Zhang; Ousheng Liu; Gang Ding; Runtao Gao; Chunmei Zhang; Yaozhong Ding; Jonathan S Bromberg; Wanjun Chen; Lingyun Sun; Songlin Wang
Journal:  Blood       Date:  2012-08-27       Impact factor: 22.113

10.  Overexpression of transcription factor Foxa2 and Hnf1α induced rat bone mesenchymal stem cells into hepatocytes.

Authors:  Yi Ding; Cuifang Chang; Zhipeng Niu; Keqiang Dai; Xiaofang Geng; Deming Li; Jianlin Guo; Cunshuan Xu
Journal:  Cytotechnology       Date:  2016-01-21       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.